Abstract
Modern pharmacotherapy of chronic coronary heart disease (HIBS) is based on the use of two main groups of drugs nitrates and beta-blockers. The effectiveness of other drugs in the complex treatment of this disease is being reviewed and constantly debated [1, 2]. The treatment of HIBS, combined with bradycardia, circulatory insufficiency, bronchospastic conditions, intolerance or contraindications to the use of nitrates and beta-blockers, is a great difficulty.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
